The Ochsner Transplant Institute has performed its 10,000th organ transplant, reflecting decades of clinical excellence and innovative care. The milestone places the institution among an elite group nationally and highlights its commitment to advancing transplant medicine.
For 15 years, Ochsner Health hospitals have ranked as the best in Louisiana for overall care, with numerous specialties and procedures recognized as High Performing by U.S. News & World Report. The hospital's obstetrics and gynecology service lines, including lung surgery, are among the top-ranked in the nation.
Ochsner Health has received multiple Get with the Guidelines achievement awards for demonstrating commitment to following research-based guidelines for treating heart disease and stroke. This recognition reflects Ochsner's unwavering commitment to clinical excellence in cardiovascular care.
Ochsner MD Anderson Cancer Center has earned two accreditations from the American College of Surgeons (ACS) Commission on Cancer and National Accreditation Program for Breast Centers. The center's multidisciplinary approach brings together specialists in cancer disciplines to support patients with complex needs. Additionally, Ochsner M...
Ochsner Health celebrated its 23rd Annual Research Week from May 18 through May 21, featuring scientific findings and recognized excellence in discovery and patient outcomes. The week also showcased award-winning lectures and presentations on cancer biology, precision medicine, and innovative clinical trials.
A study by Ochsner experts explores the cost-effectiveness of integrating behavioral health care into primary care for adults with depression, anxiety, and chronic pain. Behavioral health integration resulted in improved mental health outcomes, reduced opioid use, and lower prescription expenses, making it a cost-effective option.
Dr. Craig Sable, a pediatric cardiologist at Ochsner Children's, is part of a landmark research network aiming to advance early detection and treatment of valvular heart disease. The SHIELD Center, funded by the American Heart Association, utilizes AI technology to scale echocardiography screening for earlier RHD diagnosis.
Ochsner Baton Rouge welcomes several new physicians, including a psychiatrist and orthopedic specialists, as well as advanced practice providers. The medical center now offers expanded care options for patients with various health conditions, thanks to the addition of these specialized healthcare professionals.
The event provided free blood pressure, glucose, and cholesterol screenings, as well as colorectal cancer risk assessments with take-home test kits. Families also participated in interactive health education activities and received CPR education.
The Brain Health Collaboratory aims to accelerate the discovery, validation, and delivery of non-invasive neuroprotective therapies for cognitive decline and Alzheimer's disease. Cognito Therapeutics' Spectris technology platform will be combined with Ochsner's clinical network to explore new approaches to brain health care delivery.
Ochsner Medical Center - Baton Rouge has been ranked among the world's best hospitals by Newsweek's 2026 list, highlighting its commitment to clinical excellence and patient care. The hospital's inclusion on the list reflects its rigorous evaluation and high quality metrics, including patient experience data and expert recommendations.
Ochsner MD Anderson Cancer Center will be the first in the southern US to offer biology-guided radiotherapy (BgRT), a breakthrough treatment that uses cancer biology to guide radiotherapy delivery. This new therapy aims to provide more focused and accurate treatment with fewer side effects for patients.
Dana Bledsoe, Ochsner Children's CEO, joins the Make-A-Wish Texas Gulf Coast and Louisiana Board to further strengthen collaborative efforts to reach more children in need. The partnership has successfully granted 12 wishes and provided support to hundreds of patients and their families since its formal launch in April 2025.
Ochsner Health System has expanded its specialty physicians and advanced practice providers to improve access to care for the Baton Rouge community. New physicians include Dr. Madeleine Dehner in family medicine, Dr. Victoria Page in ear, nose and throat medicine, and Dr. Maci Petite in women's health medicine.
Tumor-infiltrating lymphocytes (TIL) therapy is a form of immunotherapy that harnesses the body's natural defenses to fight cancer. Researchers at Ochsner MD Anderson have successfully treated advanced melanoma using this innovative approach, with many patients experiencing tumor shrinkage or elimination after treatment.
Five Ochsner Health hospitals have been named among Newsweek's America's Best-in-State Hospitals 2026, exceling in clinical excellence, patient experience, and innovation. These hospitals were recognized from over 6,000 nationwide for their dedication to providing excellent care.
Ochsner MD Anderson is offering histotripsy, a revolutionary non-invasive treatment for liver tumors, approved by the FDA in 2023. The procedure uses ultrasound energy to destroy liver tumors in a single outpatient procedure.
Dr. Timothy Riddell has been appointed as the new executive vice president and chief operating officer of Ochsner Health, with a focus on guiding the system's long-term goals for sustainability and success. He brings 28 years of experience within the Ochsner group practice to his new role.
Ochsner MD Anderson Cancer Center has seven locations recertified for quality cancer care, demonstrating a commitment to comprehensive holistic care. The QOPI Certification Program recognizes these locations for meeting national standards and objectives.
Ochsner Accountable Care Network (OACN) has saved $44.8 million in 2024 while improving care for nearly 60,000 patients. The network ranked No. 3 out of 476 ACOs nationwide for care coordination and placed in the top 11% for overall quality.
Ochsner Health's Genetic Wellness Assessment is an innovative screening tool that helps identify individuals at risk for hereditary cancers. The assessment evaluates personal and family history to provide personalized cancer screening and prevention plans.
Dr. Brandon M. McElroy, MD, joins Ochsner Novant Health's 65 Plus program in Bellview, bringing nearly a decade of experience in primary care to the community. The program offers customized healthcare, social support, and wellness resources tailored to the unique needs of older adults.
Ochsner Health has been recognized as one of the best companies to work for in the U.S. by Fortune Media and Great Place to Work, based on analysis of survey responses from nearly 228,000 employees. The recognition reflects Ochsner's commitment to supporting its team members' full potential.
Ochsner Health has earned a Gold-level recognition in 2025 from the American Medical Association (AMA) for its efforts to reduce burnout and enhance professional fulfillment. The organization's dedication to evidence-based programs and services has improved team resilience and mental health support.
Pediatric orthopedic surgeons at Ochsner Children's perform the first robotic-assisted pediatric spine deformity surgery in Louisiana using Globus Medical's ExcelsiusGPS technology. The procedure enables unprecedented surgical precision and accuracy, improving patient outcomes.
Ochsner Medical Center, including Ochsner Medical Center- West Bank, Ochsner Baptist, and Ochsner Hospital for Orthopedics and Sports Medicine, has been named the Best Hospital in Louisiana for the 14th consecutive year. The hospital's Obstetrics and Gynecology service line is nationally ranked No.13 in the United States.
Dr. Abdul Khan, MD, appointed as CEO of Ochsner River Region, bringing nearly two decades of experience and leadership to the role. He will oversee facilities and care across Kenner, Luling, Destrehan, and LaPlace.
The Ochsner Health system implements pharmacogenomics to fine-tune treatments based on individual genetic profiles, transforming patient care through personalized medicine. Pharmacists play a pivotal role in spearheading these innovations, overcoming barriers and maximizing impact.
The Ochsner Transplant Institute's kidney program has achieved ELITE Status through exceptional performance and superior results. The program demonstrates high-quality care and outstanding patient outcomes, earning recognition from INTERLINK COE Networks & Programs.
A recent study published in the International Journal of Cardiology analyzed data from multiple clinical trials to assess the therapeutic impact of pulmonary artery denervation (PADN) on pulmonary hypertension patients. PADN showed significant reductions in mean right atrial pressure, mean pulmonary artery pressure, and pulmonary vascu...
Ochsner Health has earned the 2025 USA TODAY Top Workplaces award, a testament to its commitment to fostering a workplace environment that values employee listening and engagement. The organization's people-first culture results from genuine feedback and experiences among its team members.
Ochsner Health received the 2025 Gallup Exceptional Workplace Award for its innovative approach to employee development, fostering a culture of professional growth and innovation. The organization prioritizes engagement and provides resources, support, and inspiration to enable high-quality care.
Four Ochsner Health nurses have been named to the Louisiana State Nurses Association's 40 Under 40 list, recognizing their exceptional leadership qualities and commitment to the nursing profession. The recognition celebrates these nurse leaders who embody compassion and kindness, delivering high-quality care to patients and communities.
Kelly Haynie has been named chief executive officer of Ochsner Medical Center – West Bank Campus, succeeding Mary Deynoodt. With a decade of experience in driving operational excellence in acute care and outpatient settings, Haynie aligns with Ochsner's culture of innovation and patient-centered care.
A meta-analysis of 14 studies reveals that combination lipid-lowering therapy using statins and ezetimibe significantly lowers LDL cholesterol levels and diminishes cardiovascular risks. Early integration of this approach in treatment protocols can substantially curtail mortality and CVD events.
The Ochsner Children's & ISMP Safe Medication Management Fellowship aims to educate pharmacist leaders in the fight against medication errors. Participants will learn from ISMP's experts virtually and support error prevention efforts onsite at Ochsner Children's in New Orleans.
A predictive model developed by Ochsner Health researchers uses data-driven insights to determine whether urgent carotid-intervention patients will regain functional independence. The model has been shown to have a 93% accuracy rate and can help physicians tailor treatment plans and optimize intervention timing.
The network's all-new digital report boasts over $56.1 million in total cost-of-care savings, with $44.6 million in rewards shared among providers. Ochsner Health Network also expands access to care and improves health outcomes through its collaborative partnerships and technological advancements.
Ochsner Health has been chosen as a site for the Global Parkinson’s Genetics Program, a study aimed at identifying genetic links to Parkinson’s disease in underrepresented populations. The study will genotype over 150,000 individuals from around the world, providing population-specific insights into the basis of PD.
Dana Bledsoe joins Ochsner Children's as CEO, bringing extensive leadership experience and a commitment to nurturing children's dreams. With her unique approach to creative problem-solving and advocacy for team development, she aims to build a compassionate and innovative environment.
Ochsner Health hospitals have earned a Fall 2024 “A” Hospital Safety Grade from The Leapfrog Group, reflecting their commitment to excellence and patient wellbeing. The Leapfrog Hospital Safety Grade program assigns grades based on performance measures reflecting errors, accidents, injuries, and infections.
The Ochsner Accountable Care Network achieved its eighth consecutive year of top-ranking results in clinical performance and healthcare savings. The network saved Medicare $30.9 million for over 58,000 beneficiaries in 2023, improving health outcomes while reducing costs.
The Ochsner Transplant Institute collaborated with 25 US centers to conduct the first HIV-to-HIV kidney transplant study, showing comparable results between patients with and without HIV. The study's findings support the safe and effective use of HIV-positive donor organs in transplants.
A post hoc analysis of the ARCADIA trial found no significant difference in major ischemic and hemorrhagic events between apixaban and aspirin in patients with a history of cancer and cryptogenic stroke. The study suggests that both treatments may be effective, but further research is needed to confirm these results.
A recent study published in JAMA Network Open found that 84% of adults with congenital heart disease reported good or better health-related quality of life, despite complex CHD. However, participants with complex CHD were less likely to meet physical activity guidelines and reported mood disorders.
A study by Dr. Hernan Bazan at Ochsner Health reveals that higher frailty scores are directly associated with increased rates of stroke, death, and myocardial infarction within 30 days of the carotid procedure. The Hospital Frailty Risk Index provides a systematic tool for assessing frailty risk across large populations.
Bloomberg Philanthropies' $5 million gift supports the planning phase of Xavier Ochsner College of Medicine, the only historically Black medical school in the Gulf South. The new school aims to train physicians who reflect the diversity of their communities and address healthcare shortages.
A new study uses convolutional neural networks to improve nasal endoscopy accuracy and efficiency. The model achieved impressive results, identifying the inferior turbinate and middle turbinate with an average accuracy of 91.5%, precision of 92.5%, and recall of 93.8%.
The HHS competition evaluated Ochsner Connected MOM's effectiveness in increasing blood pressure measurements among Black patients and rural populations. The program saw a statistically significant increase in blood pressure measurements, benefiting over 2,000 patients.
A recent study published in JAMA Cardiology found that dual direct-current cardioversion is significantly more effective than single cardioversion in restoring sinus rhythm in obese patients with atrial fibrillation. The study demonstrated a 98% success rate for dual cardioversion, compared to an 86% success rate for single cardioversion.